Cardurion Pharmaceuticals Inc.

Cardurion Pharmaceuticals Inc. raised $260m in series B venture capital to fund ongoing Phase II clinical trials in heart failure and a rare genetic arrhythmic disease for its two lead drug candidate

From the ruins of Imara Inc. ’s dashed hopes in hemoglobinopathy indications, Enliven Therapeutics will reach the public market in a reverse merger that it says will get it to clinical data readouts

The biotechnology company creator and funder Flagship Pioneering and the Cystic Fibrosis Foundation announced a strategic partnership on 3 November under which the CF Foundation has committed up to

Cambridge, MA-based Imara Inc. , a company developing novel therapeutics for sickle cell disease, has raised $63m in a series B fundraising which could propel the company into broadening its pipeline